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A unique series of biologically active chemical probes that selectively inhibit NF-κB activation induced by
proteinkinaseC(PKC) pathwayactivatorshavebeenidentifiedthroughacell-basedphenotypicreportergene
assay. These 2-aminobenzimidazoles represent initial chemical tools to be used in gaining further under-
standing on the cellular mechanisms driven by B and T cell antigen receptors. Starting from the founding
member of this chemical series 1a (notated in PubChem as CID-2858522), we report the chemical synthesis,
SAR studies, and pharmacological profiling of this pathway-selective inhibitor of NF-κB activation.
Introduction
Membersofthenuclearfactor-kappaB(NF-κB
a) familyof
transcription factors control many crucial physiological and
pathological processes including host-defense, immune res-
ponse,inflammation,andcancer.
1,2Anumberofintracellular
signaling pathways leading to NF-κB activation have been
elucidated and have been the subject of several excellent
reviews.
3,4 Most NF-κB activation pathways converge on
IκB-R kinase (IKK) activation, resulting in phosphorylation
ofIκB-R,andtherebytargetingthisproteinforubiquitination
withproteasome-dependentdestruction.Thiscascadereleases
NF-κB heterodimers from the IκB-R complex in the cytosol
and allows for translocation into nucleus where transcription
of various pro-inflammatory genes is initiated.
5 The various
pathways upstream of IKK activation are diverse, with most
of them linked to cell surface and intracellular receptors that
sense cell damage and pathogens as well as activation in
response to cytokines. Accordingly, small molecule pathway
selective inhibitors can serve as powerful chemical tools to
dissectthesemolecularnetworkswhicharecrucialfornormal
cellularsurvivalbutaredysregulatedinspecificdiseasestates.
The NF-κB pathway activated by antigen receptors is critical
for adaptive immunity contributing to T and B lymphocyte
activation, proliferation, cell survival, and effector functions.
Dysregulated NF-κB activation in lymphocytes contributes to
development of a variety of autoimmune-based disease states,
chronicinflammation,andlymphoidmalignancy.
6,7TheNF-κB
activation pathway linked to antigen receptors involves a
cascade of adapter and signal transduction proteins that at
minimum include a CARMA family protein, Bcl-10, MALT
(paracaspase), TRAF6, Ubc13, caspase-8, and c-Flip. Forma-
tion of this complex is initiated by protein kinase C (PKC)-
mediated phosphorylation of CARMA proteins. In T and B
cells, this pathway is initiated by PKC-θ and PKC-β,r e s p e c -
tively, leading ultimately to IKK activation through a mecha-
nism potentially involving lysine 63-linked polyubiquitination
of IKK-γ.
8 Thus, the antigen receptor pathway for NF-κB
activation is both initiated and concluded by activation of
protein kinases, namely the PKCs and IKKs, respectively.
Although the IKK complex and its individual subunits
represent logical targets for potential drug discovery, small-
molecule inhibitors of IKKs suppress all known NF-κB
activation pathways. This approach lacks the selectivity re-
quired to inhibit lymphocyte responses without simulta-
neously interfering with overall innate immune responses
and leads to general immunosuppression attended by risk of
pathogenic infection as well as other severe side effects.
9,10
A library of approximately 110,000 compounds from the
NIH Molecular Libraries Small Molecule Repository
(MLSMR) compound collection was screened using a
HEK293 cell-based NF-κB luciferase reporter gene strategy.
11,12
Primary hit compounds with an IC50e10 μMw e r ef u r t h e r
characterizedby14additionalcell-basedcounter-screensthat
helped determine pathway selectivity in the HEK293 cell line
and other lymphocytes. Ultimately, three hit series emerged
and were confirmed through an extensive counter-screen
assay platform to be selective for the antigen receptor activa-
tion pathway (Figure 1A). Of the three primary hit classes
identifiedintheHTScampaign,onlythe2-aminobenzimidazole
series represented by 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-
2-(2-((3-hydroxypropyl)amino)-5,6-dimethyl-1H-benzo[d]-
imidazol-1-yl)ethanone, 1a (CID-2858522), selectively inhib-
ited the NF-κB pathway induced by PKC activators and
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aAbbreviations: PKC, protein kinase C, NF-κB, nuclear factor-
kappa B; IκB, inhibitor of NF-κB; IKK, ΙκB-R kinase; CARMA,
caspase recruitment domain (CARD) carrying member of the mem-
brane associated guanylate kinase (MAGUK) family proteins; Bcl-10,
B-cell lymphoma/leukemia 10 protein; MALT, mucosa associated
lymphoid tissue translocation protein; TNF-R, tumor necrosis factor
alpha; TRAF, TNF receptor associated factor; Ubc13, ubiquitin con-
jugating enzyme 13; c-FLIP, cellular Fas-associated death domain-like
IL-1-converting enzyme inhibitory protein; HTS, high throughput
screening;MLSMR,NIHmolecularlibrariessmallmoleculerepository;
HEK293, human embryonic kidney 293 cells; IL-8, interleukin-8; CD,
cluster of differentiation; PMA, phorbol-12-myristate-13-acetate; CID,
compound ID; SAR, structure-activity relationship; ADME/T, ab-
sorption,distribution,metabolism,excretion,andtoxicology;PAMPA,
parallel artificial membrane permeability assay; CYP3A4, cytochrome
P450 3A4; NIMH-PDSP, National Institute of Mental Health Psy-
choactive Drug Screening Program; MLPCN, The Molecular Libraries
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antigen receptors. Compound 1a did not inhibit activation of
NF-κB through TNF-R stimulation (Figure 1B). Details of
the comprehensive screening platform and pathway speci-
fic cell-based selectivity assessment, as outlined above, are
described in our accompanying paper.
13
On the basis of the above information and selectivity profile,
the 2-aminobenzimidazole series was selected for chemistry
follow-up as it met our initial potency criteria (<1 μM) and
selective inhibition of antigen receptor-mediated NF-κB activa-
tion. We discuss the development of an efficient synthetic route
to the 2-aminobenzimidazole scaffold, the design and synthesis
of SAR analogues, as well as in vitro and in vivo pharmacolo-
gical profiling of 1a. These structure-activity relationship
studies provide molecular insight for further optimization and
synthesis of proteomic probes, which include analogues to be
used for the identification of the precise cellular target protein
and subsequent mode of action studies.
Results and Discussion
The initial HTS hit compounds of interest (Figure 1) were
resynthesized so that identity and cellular activity could be
confirmed. Additional commercially available dry powder sam-
ples for closely related analogues were ordered (ChemBridge
Corporation, San Diego, CA), and the quality, purity, and
identity for each compound was confirmed. In the case where
the commercial analogues were not homogeneous, they were
purified by preparative HPLC to g98%. Each compound was
assessed for bioactivity using a cell-based assay employing
HEK293 cells containing a stably integrated NF-κB-luciferase
reporter gene, which was stimulated with phorbol-12-myristate-
13-acetate (PMA) and ionomycin.
The “analogue by catalogue” approach ultimately provided
an initial set of 2-aminobenzimidazoles having NF-κB-lucifer-
aseIC50 valuesinthemicromolartonanomolarrangeasshown
in Figure 1S (see Supporting Information). Analysis of the
structure-activity relationships (SAR) pointed to features re-
sponsible for optimal activity. Truncation of 2-aminopropanol
substituentandremovalofboth5-and6-methylgroupsresulted
in equipotent inhibitors (compounds 4 and 5, Figure 1S, see
Supporting Information). Most importantly, the di-t-butyl
phenol moiety present in the N1-acetophenone substituent of
the 2-aminobenzimidazole scaffold seemed to be essential for
activity (compounds 1a and 6-8, Figure 1S, see Supporting
Information). 3,5-Di-t-butyl-4-methylphenol and 6,60-methyl-
enebis-(2-tert-butyl-4-methylphenol), commercial antioxidants
were screened and found to be inactive, thus ruling out any
connection between a potential antioxidant pharmacophore
(possibly affecting nitric oxide signaling) and observed NF-κB
inhibitory activity of 1a (compounds 9 and 10, Figure 1S, see
Supporting Information).
14 The general synthetic route toward
thetargetedseriesisillustratedinScheme1.Thedesiredscaffold
was accessed from the corresponding 2-bromobenzimidazole
intermediate (Scheme 1).
Accordingly, the aryl diamine 11a was condensed with
potassium ethyl xanthate in ethanol at reflux to afford 12a,
which on bromination furnished the key 2-bromo-5,6-di-
methylbenzimidazole intermediate 13a.
15-17 Amination of
13a with 3-aminopropanol under neat conditions at high
temperatureaffordedthehighlypolarintermediate14a,which
required extensive chromatography for purification.
18 It was
found that conducting the amination reaction under solvent-
free microwave heating conditions at 180 C/25 min afforded
14a in high yield and purity after simple extraction.
Thefinalalkylationofintermediate14awithR-bromo-3,5-di-
tert-butyl-4-hydroxyacetophenone (15a) was conducted in
n-butanol at reflux to furnish 1a in moderate yield (Scheme 1,
method A). The low isolated yield was attributed to the forma-
tionoftricyclicsideproduct16viaanintramolecularSchiff-base
formation.
19Purified16wasfoundtobeinactive(IC50>25 μM)
under the assay conditions. This competing intramolecular
cyclization was completely eliminated by conducting the reac-
tion at 23 C in methanol using sodium bicarbonate as a mild
base. Although alkylation under these conditions was incom-
plete even after 3 days, the formation of 16 was attenuated and
compound 1a was obtained in 78% yield and in >98% purity
(Scheme 1, method B). The optimized route was utilized for
the synthesis of an analogue library designed to explore, (a)
monosubstitution at 5- and 6-positions of 2-aminobenzimida-
zole core, (b) substitution at the 2-position with diverse amines,
(c) substitution of the aryl ring of the N1-acetophenone moiety,
and (d) replacement of the core 2-aminobenzimidazole with
related 2H-benzimidazole and benzimidazolone ringsystems.
Commercially available 4-monosubstituted-phenyl-1,2-dia-
mines were converted to the corresponding 2-aminobenzimi-
dazoles (14b,d,e, Scheme 1) via the corresponding 2-bromo
intermediates (13b,d,e).
Subsequentalkylationwith15aunderpreviouslyoptimized
conditions furnished the regioisomeric 5- and 6-substituted
benzimidazole analogues (1b,d,e; 17b,d,e), which could be
separated by chromatography and characterized. The 5- and
6-bromo analogues (1b and 17b), when subjected to the
Suzuki coupling protocol with phenyl boronic acid, afforded
5-and6-phenylsubstitutedanalogues1cand17c,respectively.
The 5- and 6-nitro analogues (1eand17e) werereduced to the
corresponding aminocompounds 1fand17f, respectively, via
hydrogenation. A variety of amines were then reacted with
3a under the previously optimized amination conditions.
Subsequent alkylation with 15a generated the corresponding
2-aminoalkylsubstitutedanalogues(1g-1k,Scheme2A).The
analogue library was then evaluated for inhibition of NF-κB
activation using the cell-based HEK293 NF-κB luciferase
reporter gene assay.
12,13
Tostudy the effect of variation of substitutionon thearylring
at the N1-position of 1a, suitably substituted R-bromoacetophe-
nones were synthesized (15l-15n) from commercially available
Figure 1. (A) Three scaffold classes (with IC50 <1 0μM, most
active members shown) identified in the high throughput screening
(HTS) campaign. (B) Selectivity of 1a for inhibition of the NF-κB
antigen receptor pathway induced by PMA (a PKC activator) vs
TNF-R activation.Brief Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 12 4795
starting materials and then treated with intermediate 14a to
accessanalogues1l-1n(Scheme2B;seeSupportingInformation
fordetails).Toreplacethe2-aminobenzimidazolecoreof1awith
related heterocycles, commercially available 5,6-dimethyl-1H-
benzimidazole and 5,6-dimethyl-1H-benzimidazol-2-one were
alkylated with 15a in the presence of sodium hydride to furnish
18 and 19 in 63 and 55% yield, respectively (Scheme 3).
Through a systematic substitution process, we probed the
individual contribution of the substituents at the 5- and
6-positions of the benzimidazole aryl moiety. It was found that
substituents at the 5-position were better tolerated than at
6-position and activity of analogues was sensitive to both the
electronic and steric nature of the substituents (1b-fand 17b-f,
Table 1A). The results indicate that the 6-position is more
sensitive to the steric bulk of the substituent than the 5-position
because replacement of either methyl group with a bromine led
to a 40-8 0 - f o l dd r o pi na c t i v i t y( 1a, 1b,a n d17b,T a b l e1 A ) .
Similarly, the 5-nitro analogue was 20-fold less active than
1awhilethe6-nitroanaloguewasfoundtobeinactive(1eand
17e, Table 1A). Installation ofa planarphenyl group resulted
inanalogueswithactivityapproachingthatof1a,suggestinga
positivehydrophobicinteractionatthe5-position(1cand17c,
Table 1A). An unexpected result was that the 5- and 6-amino
analogues were the most active analogues in this substitution
series,suggestingaccesstoH-bondinginteractions(1fand17f,
Table 1A). It was found that while O-methylation of the
2-aminopropanol side chain retained most of the activity
(1g, Table 1B), removal of the hydroxyl substituent in the
2-butylamino analogue led to a moderate loss of activity (1h,
Table 1B), suggesting that the electronegative oxygen atom is
not essential for activity. Truncation of the butyl group in the
2-methylamino analogue led to improved activity and was
found to be as potent as 1g (1i, Table 1B). Replacement of
2-aminopropanol side chain with a conformationally res-
tricted 4-hydroxycyclohexylamine did not result in any im-
provement over 1a (1j, Table 1B). The presence of a tertiary
amine at the benzimidazole 2-position was found to abolish
activity (1k, Table 1B). These results, taken together, suggest
that the entire 2-aminopropanol substituent is likely solvent
exposed and may not be completely required (except the NH
moiety) for binding to the cellular target protein.
Replacement of the N
1-3,5-dimethyl-4-hydroxyacetophe-
none with either simple acetophenones or 3,5-dimethyl-4-
hydroxyacetophenone resulted in complete loss of activity
(6-10, Figure 1S, see Supporting Information). It was found
that the des-4-phenoxy analogue retained complete activity
(1l, Table 1C), and hence the 4-phenoxy substituent is not
essential for activity, further confirming that NF-κB inhibi-
tion is not due to antioxidant activity. The SAR for aryl
substitution at this position is steep. Elimination or replace-
ment of one of the tert-butyl groups with a tert-butoxy group
resulted in completely inactive analogues, suggesting that the
di-tert-butyl phenyl group might represent a conformational
lock and is extremely important for binding/activity (1m and
1n, Table 1). Replacement of the 2-alkylamino moiety with
hydrogen led to a significant loss of activity, however, the
2-benzimidazolone analogue was essentially equipotent to 1a
(18 and 19, Figure 2). These results indicate that a polar
heteroatom is needed at the 2-position for activity, yet the
2-amino group is completely replaceable. This observation has
important bearing on future probe SAR because it allows
further derivatization at the N
3 position allowing exploration
of additional chemical space via alkylation or acylation.
Scheme 1. Synthetic Route to 1a and Monosubstituted Benzimidazole Analogues 1b-f and 17b-f
Scheme 2. Synthesis of (A) 2-Aminoalkyl Benzimidazoles
1g-1k; (B) Analogues 1l-1n with Substitution on the Aryl N1
Position
Scheme 3. Synthesis of 2-H-Benzimidazole and 2-Benzimida-
zolone Analogues4796 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 12 Peddibhotla et al.
TheSARindicatestheentire2-aminopropylchaindoesnot
contribute significantly to bioactivity. Because the precise
cellular protein target is unknown, we capitalized on this
information to synthesize two analogues that have an azide
and a terminal alkyne incorporated in the 2-aminoalkyl side
chain (1o, 1p, Figure 2). The objective was to utilize these as
building blocks for the synthesis of pull down probes for
protein target identification. We were gratified that both
analogues retain sufficient bioactivity (within 6-fold) and
are currently being utilized in ongoing studies involving
bioconjugation via “click chemistry” to furnish biotinylated
derivatives for affinity studies.
InVitroandinVivoPharmacologicalProfiling.Compound
1a was subjected to in vitro ADME/T assays to profile its
generalpharmacologicalproperties(Table2).Compound1a
exhibits good to moderate solubility across pH ranges and
moderate to high “effective” cell permeability (PAMPA).
Although plasma stability is good, the probe exhibits high
affinity toward plasma protein binding, possibly limiting
available in vivo free fraction concentration. The compound
was found to be nontoxic to human hepatocytes (Fa2N-4
cells; LD50 =4 7μM) and in the HEK293 cell line (LD50>
50 μM) used in the primary activity assay. Compound 1a is
moderately stable to human hepatic microsomes at 1 and 10
μMbutwasrapidlymetabolizedbymurinemicrosomes.1ais
a weak inhibitor of CYP 3A4 (IC50 =3μM).
In vivo dose-exposure profiling of1a was conducted using
a small cohort of three male mice was subjected to single ip
doses at 10, 30, and 50 mg/kg. Blood was drawn at 0.5 and
3 h, and subsequent LC/MS analysis of pooled samples was
performed to determine the overall blood levels of com-
pound (Table 3). Probe compound 1a exhibited nonlinear
pharmacokinetics, showing higher serum levels at the 0.5 h
measurement time for the 30 mg/kg dose compared to
50 mg/kg but displaying typical dose-dependent behavior
whenmeasuredatt=3h.Theincreasingaccumulationseen
at a dose of 50 mg/kg may be due to a depot effect created
by CYP3A4 inhibition. The cohort exhibited clear signs of
morbidityatt=3hatthe50mg/kgdose.Onthebasisofthe
above data, blood levels can be expected to reach maximum
concentrations approximately 10-fold higher than IC50 at a
dose of 30 mg/kg, thus defining a promising dose for future
applications in short-term, acute biomarker studies such as
in vivo measurements of cytokine production.
General Target Inhibition Profile. Protein kinases play
critical roles in NF-κB activation. PKCs are proximal kinases
in the NF-κB pathways activated by PMA/ionomycin and by
T-cell and B-cell antigen receptors, while the IKKs are distal
kinases operating in the terminal segments of these and other
NF-κBactivationpathways.
2Atconcentrationsupto8μM,1a
f a i l e dt os u p p r e s sP K C - β and PKC-θ (the PKC family mem-
bers implicated in TCR/BCR signaling), and IKK-β (a com-
ponent of the IKK complex), while known PKC and IKK
inhibitors and the broad-spectrum kinase inhibitor stauros-
porine afforded potent inhibition.
12,13 In addition, 1a did not
inhibit endogenous PKC activity or phosphorylation of down-
stream substrates.
13 Probe 1a did not directly inhibit PKC-β,
PKC-θ,orIKK-β.Abroadkinomescreenwasthenconducted
using KINOMEscan (Ambit Biosciences) platform. Of 353
protein kinases surveyed, 1a inhibited only three by more than
50% at 10 μM; Raf (57% inhibition), TLK1 (70% inhibition),
and JAK2 (53% inhibition), none of which are clearly impli-
c a t e di nN F - κB regulation.
Compound 1a was screened for general functional activity to
determine effects on second messenger systems using a subset of
clonedhumanorrodentreceptors,ionchannels,andtransporters
(NIMH-PDSP, University of North Carolina Chapel Hill).
Of the 92 targets screened, 1a showed greater than 50%
Table 1. Analogue SAR (A) 5 and 6-Monosubstitution of the Benzimi-
dazole Core, (B) Substitution at the 2-Position, and (C) Substitution on
the Aryl N
1-Acetophenone Moiety
Figure 2. Bioactivity of 2H-benzimidazole 18, 2-benzimidazolone
19, azide 1o, and alkynyl ester 1p.
Table 2. In Vitro ADME Data for 1a
plasma protein
binding (% bound)
microsome stability
d
(% remaining) solubility
(μg/mL)
pH 5.0/6.2/7.4
permeability
a,b Pe ( 10
-6 cm/s)
pH 5.0/6.2/7.4
human
10 μM/1 μM
mouse
10 μM/1 μM
plasma stability
c
(% remaining)
human/mouse
human
10 μM/1 μM
mouse
10 μM/1 μM
42/0.5/0.7 299/710/441 99.8/99.9 99.9/99.8 100/100 55/26 19/0.5
aCompoundat50μM.
bPAMPAPe:low5 10
-6,moderate250 10
-6,high1000 10
-6.
cPlasma/PBS;compoundat40μM,3h.
d%remainingat1h.
Table 3. In Vivo Exposure Data for 1a
dose
(mg/kg)
concentration
(μM) 0.5 h
concentration
(μM) 3 h
10 1.81(0.41 0.50(0.04
30 8.28(0.20 3.64( 0.76
50 5.93(1.30 6.96(0.76Brief Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 12 4797
inhibition at 10 μM for only eight targets (see Supporting
Information for details). For all active targets assessed, the
subsequent IC50 values were greater than 5 μM, highlighting
that 1a does not exhibit significant off-target activity.
20
Conclusions
A series of substituted 2-aminobenzimidazoles has been
identified that serve as promising research tools as pathway-
selective chemical inhibitors of NF-κB activation induced by
activators of PKC signaling through B and T cell antigen
receptors. Interestingly, the MLPCN probe candidate (1a)
was identified directly from the screening hit set and only
lesserorequipotentanalogueshavebeenprepared,indicating
a limited SAR for the series. Compound 1a was found to be
noncytotoxic and inhibited IL-8 production induced by PKC
activators in HEK293 cells (IC50<0.1 μM), while failing to
inhibit NF-κB reporter gene activation by agonists of the
other NF-κB activation pathways. Compound 1a attenuated
CD3/CD28andPMA/ionomycin-inducedproductionofIL-2
by Jurkat T-cells (IC50<5 μM) and anti-IgM-stimulated pro-
liferation of murine B-lymphocytes (IC50 ∼2 μM). We have used
the SAR data to generate the azide and alkynyl containing
derivatives 1o and 1p. These have been utilized in the synthesis
of biotinylated conjugates directed toward affinity-based target
identification and future mode of action studies that will be
reported separately. In addition, the equipotent 2-benzimid-
azolone analogues (19) provide a modified scaffold with an
additional N3-site for future exploration. Compound 1a and its
analoguesrepresentnewchemicaltoolsthatmaybeusefultoward
further development of therapeutically useful pathway selective
modulatorsofNF-κBactivitythatmayfindapplicationindisease
models of inflammation, cancer and other autoimmune diseases.
Experimental Section
General Procedure (Method B, Scheme 1) of N1-Alkylation of
2-Aminobenzimidazoles for the Synthesis 1a, 1b, 1d, 1 e, 1g-n,
17a, 17b, 17d, and 17e as Illustrated by Synthesis of 1-(3,5-Di-
tert-butyl-4-hydroxyphenyl)-2-(2-(3-hydroxypropylamino)-5,6-
dimethyl-1H-benzo[d]imidazol-1-yl)ethanone, 1a. To a 20 dram
vial equipped with a stir bar was added 2-aminobenzimidazole
14a (0.37 g, 1.6 mmol) followed by corresponding 2-bromoace-
tophenone 15a (0.62 g, 1.9 mmol). To the mixture was added
10 mL of methanol and solid NaHCO3 (3 equiv). The mixture
was stirred at 23 C for 3 days, after which the solvent was
evaporated to a suitable volume and subsequent purification by
silicagelflashcolumnchromatography(hexanesto1:4hexanes/
ethyl acetate) resulted in a yellow film, which on lyophilization
from a 2:8 acetone/water mixture afforded 1a as white solid
(0.61 g, 78%).
1H NMR (400 MHz, acetone-d6) δ 7.87 (s, 2H),
6.95(s,1H),6.77(s,1H),5.94(s,1H),5.52(s,2H),3.55-3.47(m,
2H), 3.42 (t, J = 5.6 Hz, 2H), 2.14 (s, 2H), 2.12 (s, 3H), 1.56 (p,
J=6.0Hz,2H),1.40(s,18H).
13CNMR(100MHz,acetone-d6)
δ 191.58, 159.66, 156.73, 141.17, 137.58, 134.43, 128.85, 127.29,
127.19, 126.16, 116.74, 108.72, 57.65, 48.47, 39.19, 34.90, 34.67,
19.77, 19.74. LRMS (ESI): calcd for C28H39N3O3 [M þ H] =
466.3, obsd [MþH]=466.1. HRMS (ESI): calcd for C28H39-
N3O3 [M þ H] = 466.3070, obsd [M þ H] = 466.3091.
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